SCHEMBL9963114

SCHEMBL9963114

CC(C)N1CC(Oc2cncc(Cl)n2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 2/20 0.33
▸ SLC6A4 P31645 2/20 0.33
▸ HTR2A P28223 2/20 0.31
▸ DRD2 P14416 1/20 0.31
▸ HRH1 P35367 1/20 0.31
▸ TLR9 Q9NR96 1/20 0.31
▸ TLR8 Q9NR97 1/20 0.31
▸ TLR7 Q9NYK1 1/20 0.31
▸ PDE9A O76083 1/20 0.31
▸ CDK2 P24941 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ HTR1A P08908 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ HTR2C P28335 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9965911 0.83 CHRNB2 (0.33) SLC6A4HTR2ATLR7CDK2KDM4E
SCHEMBL20772699 0.77 CDK2 (0.39) HTR2ACDK2KDM4EMEN1ALDH1A1
SCHEMBL24188504 0.76 SLC6A4 (0.35) SLC6A4PDE9A
SCHEMBL31080558 0.76 CHRM2 (0.39) SLC6A4HTR2C
SCHEMBL31080112 0.76 CHRM2 (0.39) SLC6A4HTR2C
SCHEMBL9364949 0.75 SLC6A3 (0.45) DRD2MEN1CYP1A2CYP3A4CYP2C19
SCHEMBL3664003 0.75 KCNH2 (0.37) CDK2
SCHEMBL9364955 0.75 SLC6A3 (0.45) DRD2MEN1CYP1A2CYP3A4CYP2C19
SCHEMBL31080235 0.75 SLC6A3 (0.45) DRD2MEN1CYP1A2CYP3A4CYP2C19
SCHEMBL23012711 0.74 MET (0.39) HRH3CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 — — US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 HRH3 250/4885SLC6A4 1928/4885HTR2A 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback